TraffikGene
Startup
Spain
Summarized by Halo AI
TraffikGene is a biotech venture developing a proprietary, non-viral peptide-based gene delivery platform designed to improve the safety, targeting, and efficacy of nucleic acid therapeutics for oncology and metabolic diseases.
Founded & HQ
Santiago de Compostela, Spain
Company size
1-10 employees
IP status
2 grants confirmed
Activity highlights
Signed a research collaboration with Circio to assess delivery of circVec circular RNA expression vectors for gene and cell therapy applications.
TraffikGene is a project and developing spin-off activity associated with the Universidad de Santiago de Compostela (USC) and its CiQUS center, focused on proprietary non-viral peptide-based nucleic acid delivery technology. It is structured around advancing the TraffikGene platform from preclinical validation toward commercialization through industrial translation, regulatory-enabling studies, and partnerships.
AI summary generated on Jun 4, 2026
OpenAlex
OpenAlexFor general inquiries
AF
Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.